Stephanie Shiau1, Michael T Yin2, Renate Strehlau3, Megan Burke3, Faeezah Patel3, Louise Kuhn4,5, Ashraf Coovadia3, Shane A Norris6, Stephen M Arpadi3,4,5,7. 1. Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ. 2. Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 3. Empilweni Services and Research Unit, Department of Pediatrics and Child Health, Rahima Moosa Mother and Child Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 4. SAMRC/Wits Developmental Pathways for Health Research Unit (DPHRU), G.H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY. 5. Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY. 6. SAMRC/Wits Developmental Pathways for Health Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and. 7. Department of Pediatrics, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY.
Abstract
BACKGROUND: Reduced bone mineral mass by dual x-ray absorptiometry is reported in children living with HIV (CLWH), but few studies of bone microarchitecture, particularly in sub-Saharan Africa, have been conducted. Here, we compare bone architecture and strength in black South African CLWH and uninfected control children by peripheral quantitative computed tomography (pQCT). SETTING AND METHODS: One hundred seventy-two CLWH on antiretroviral therapy (ART) and 98 controls in the CHANGES Bone Study in Johannesburg, South Africa received pQCT scans of the radius and tibia. Measurements included trabecular and cortical volumetric bone mineral density (vBMD) and bone strength, estimated by the polar strength strain index (SSI), a validated measure of fracture risk. RESULTS: CLWH (51% boys) and controls (63% boys) were an average of age 10.4 years. Mean ART duration for CLWH was 9.5 years, with 70.9% on an efavirenz-based, 28.5% on a lopinavir/ritonavir-based, and 1 child on an atazanavir/ritonavir-based regimen. Male CLWH had lower trabecular vBMD at the radius than controls after adjustment for age, radial length, and Tanner stage (β = -17.3, standard error = 7.2, P = 0.018). Bone strength by polar SSI was lower in CLWH than controls (778 vs. 972 mm, P < 0.01). CLWH on an LPV/r-based regimen had lower trabecular vBMD (199 vs. 222 mg/cm, P < 0.001) and cortical vBMD (1074 vs. 1093 mg/cm, P = 0.004) than those on an efavirenz-based regimen. No difference in bone strength by polar SSI was observed between treatment groups. CONCLUSION: CLWH initiated on ART early in life with well-controlled HIV have deficits in bone architecture and reductions in bone strength as detected by pQCT.
BACKGROUND: Reduced bone mineral mass by dual x-ray absorptiometry is reported in children living with HIV (CLWH), but few studies of bone microarchitecture, particularly in sub-Saharan Africa, have been conducted. Here, we compare bone architecture and strength in black South African CLWH and uninfected control children by peripheral quantitative computed tomography (pQCT). SETTING AND METHODS: One hundred seventy-two CLWH on antiretroviral therapy (ART) and 98 controls in the CHANGES Bone Study in Johannesburg, South Africa received pQCT scans of the radius and tibia. Measurements included trabecular and cortical volumetric bone mineral density (vBMD) and bone strength, estimated by the polar strength strain index (SSI), a validated measure of fracture risk. RESULTS: CLWH (51% boys) and controls (63% boys) were an average of age 10.4 years. Mean ART duration for CLWH was 9.5 years, with 70.9% on an efavirenz-based, 28.5% on a lopinavir/ritonavir-based, and 1 child on an atazanavir/ritonavir-based regimen. Male CLWH had lower trabecular vBMD at the radius than controls after adjustment for age, radial length, and Tanner stage (β = -17.3, standard error = 7.2, P = 0.018). Bone strength by polar SSI was lower in CLWH than controls (778 vs. 972 mm, P < 0.01). CLWH on an LPV/r-based regimen had lower trabecular vBMD (199 vs. 222 mg/cm, P < 0.001) and cortical vBMD (1074 vs. 1093 mg/cm, P = 0.004) than those on an efavirenz-based regimen. No difference in bone strength by polar SSI was observed between treatment groups. CONCLUSION: CLWH initiated on ART early in life with well-controlled HIV have deficits in bone architecture and reductions in bone strength as detected by pQCT.
Authors: Stephen M Arpadi; Mary Horlick; John Thornton; Patricia A Cuff; Jack Wang; Donald P Kotler Journal: J Acquir Immune Defic Syndr Date: 2002-04-15 Impact factor: 3.731
Authors: Michael T Yin; Emily Lund; Jayesh Shah; Chiyuan A Zhang; Marc Foca; Natalie Neu; Kyle K Nishiyama; Bin Zhou; Xiangdong E Guo; John Nelson; David L Bell; Elizabeth Shane; Stephen M Arpadi Journal: AIDS Date: 2014-01-28 Impact factor: 4.177
Authors: Linda A DiMeglio; JiaJia Wang; George K Siberry; Tracie L Miller; Mitchell E Geffner; Rohan Hazra; William Borkowsky; Janet S Chen; Laurie Dooley; Kunjal Patel; Russell B van Dyke; Roger A Fielding; Yared Gurmu; Denise L Jacobson Journal: AIDS Date: 2013-01-14 Impact factor: 4.177
Authors: Emily M Stein; Anna Kepley; Marcella Walker; Thomas L Nickolas; Kyle Nishiyama; Bin Zhou; X Sherry Liu; Donald J McMahon; Chiyuan Zhang; Stephanie Boutroy; Felicia Cosman; Jeri Nieves; X Edward Guo; Elizabeth Shane Journal: J Bone Miner Res Date: 2014 Impact factor: 6.741
Authors: Denise L Jacobson; Jane C Lindsey; Catherine M Gordon; Jack Moye; Dana S Hardin; Kathleen Mulligan; Grace M Aldrovandi Journal: AIDS Date: 2010-03-13 Impact factor: 4.177
Authors: Nicola J Crabtree; Asma Arabi; Laura K Bachrach; Mary Fewtrell; Ghada El-Hajj Fuleihan; Heidi H Kecskemethy; Maciej Jaworski; Catherine M Gordon Journal: J Clin Densitom Date: 2014-03-29 Impact factor: 2.617
Authors: Asante R Kamkwalala; Ankita Garg; Upal Roy; Avery Matthews; Jose Castillo-Mancilla; Jordan E Lake; Giada Sebastiani; Michael Yin; Todd T Brown; Angela R Kamer; Douglas A Jabs; Ronald J Ellis; Marta Boffito; Meredith Greene; Sarah Schmalzle; Eugenia Siegler; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2021-09-20 Impact factor: 2.205
Authors: Arnold Z Olali; Kelsey A Carpenter; Maria Myers; Anjali Sharma; Michael T Yin; Lena Al-Harthi; Ryan D Ross Journal: Curr HIV/AIDS Rep Date: 2022-06-20 Impact factor: 5.495